Panel discussion

Atherosclerosis Supplements

Volumn 8, Issue 2 SPEC. ISS., 2007, Pages 19-24

  Matsuzawa, Y ^a   Kita, T ^b   Shepherd, J ^c   Gotto Jr , A M ^d   Nakamura, H ^e   Sacks, F M ^f   Oikawa, S ^g   Sasaki, J ^h  

^a SUMITOMO HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Mitsukoshi Health and Welfare Foundation   (Japan)

^f HARVARD MEDICAL SCHOOL   (United States)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

HMG CoA reductase inhibitors (statins); MEGA Study (Japan); Pravastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LOW DRUG DOSE; PRIMARY PREVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CONFERENCE PAPER; FEMALE; MALE; PATIENT SELECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; TIME;

CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PATIENT SELECTION; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547677710     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2007.02.004     Document Type: Note

References (12)

1. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335 (1996) 1001-1009
2. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
3. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
4. Nakamura H., Arakawa K., Itakura H., et al., For the MEGA Study Group. Primary prevention of cardiovascular disease in Japan: results of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) randomized study with pravastatin. Lancet 368 (2006) 1155-1163
5. Mohrschladt M.F., Van der Sman-de Beer F., Hofman M.K., et al. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet 13 (2005) 877-882
6. Iakoubova O.A., Tong C.H., Chokkalingam A.P., et al. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arterioscler Thromb Vasc Biol 26 (2006) 2763-2768
7. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
8. Fager G., and Wiklund O. Cholesterol reduction and clinical benefit. Are there limits to our expectations?. Arterioscler Thromb Vasc Biol 17 (1997) 3527-3533
9. Arai H., Yamamoto A., Matsuzawa Y., et al. Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb 12 (2005) 98-106
10. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl J Med 338 (1998) 86-93
11. Hirano K., Yamashita S., Nakajima N., et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17 (1997) 1053-1059
12. Yamashita S., Maruyama T., Hirano K., et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 152 (2000) 271-285